TRAVATAN Z's oppositions filed in EPO
TRAVATAN Z Litigations
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8323630 | NOVARTIS | Self-preserved aqueous pharmaceutical compositions |
Sep, 2027
(3 years from now) | |
| US8388941 | NOVARTIS | Self preserved aqueous pharmaceutical compositions |
Sep, 2027
(3 years from now) | |
| US8268299 | NOVARTIS | Self preserved aqueous pharmaceutical compositions |
Oct, 2029
(6 years from now) | |
Travatan Z is owned by Novartis.
Travatan Z contains Travoprost.
Travatan Z has a total of 3 drug patents out of which 0 drug patents have expired.
Travatan Z was authorised for market use on 21 September, 2006.
Travatan Z is available in solution/drops;ophthalmic dosage forms.
The generics of Travatan Z are possible to be released after 13 October, 2029.
Drugs and Companies using TRAVOPROST ingredient
Market Authorisation Date: 21 September, 2006
Treatment: NA
Dosage: SOLUTION/DROPS;OPHTHALMIC
How can I launch a generic of TRAVATAN Z before it's drug patent expiration?
More Information on Dosage
TRAVATAN Z family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic